Drug
Bn83495
Bn83495: highest development phase Phase 1, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| BN83495 (Cohort 1) NCT00790374 | Phase 1 | Prostate Cancer |
Latest
No recent events.
Follow Bn83495 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.